Nimbus Discovery Obtains $24,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f73bbff3-5e1e-4d1e-825d-2f07f8ab53f6&Preview=1 - Date
6/28/2011 - Company Name
Nimbus Discovery - Mailing Address
25 First Street Cambridge, MA 02141 - Company Description
Nimbus Discovery is applying advances in computer-based drug discovery to unlock fundamental biological pathways. Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets, IRAK4 and ACC, which are pivotal to the progression of an aggressive subtype of non-Hodgkin’s lymphoma and obesity, respectively. - Website
http://www.nimbusdiscovery.com - Transaction Type
Venture Equity - Transaction Amount
$24,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds from the financing will be used to accelerate existing programs targeting IRAK4 and ACC, in inflammation, cancer and metabolic disease, and to expand the Nimbus pipeline to include a series of new targets addressing important medical conditions. - M&A Terms
- Venture Investor
Atlas Venture - Venture Investor
SR One - Venture Investor
Lilly Ventures - Venture Investor
Cascade Investment
